54 related articles for article (PubMed ID: 9951423)
1. [Adjuvant treatment of cancer of the breast: cost assessment of the protocol used].
Selke B; Bercez C; Lenne X; Bonneterre ME; Lebrun T; Bonneterre J
Bull Cancer; 1998 Nov; 85(11):961-6. PubMed ID: 9951423
[TBL] [Abstract][Full Text] [Related]
2. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
4. [Advanced breast cancer: an evaluation of the cost of recurrence].
Bercez C; Lebrun T; Bonneterre ME; Selke B; Lenne X; Bonneterre J
Bull Cancer; 1999 Jun; 86(6):585-90. PubMed ID: 10417432
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
6. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
7. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
Naeim A; Keeler EB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.
Kellokumpu-Lehtinen P; Bergh J; Salminen E; Wiklund T; Lehtinen S; Aronen P; Sintonen H
Acta Oncol; 2007; 46(2):146-52. PubMed ID: 17453362
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
10. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature.
Kilian R; Porzsolt F
Breast; 2005 Dec; 14(6):636-42. PubMed ID: 16183288
[TBL] [Abstract][Full Text] [Related]
11. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL
Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
[TBL] [Abstract][Full Text] [Related]
13. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
J Med Econ; 2012; 15(6):1167-75. PubMed ID: 22853442
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
16. [Cost of treatment and follow up of breast cancer: a retrospective assessment in a comprehensive cancer centre].
Lilliu H; Stevens D; Brun C; Morel J; Pen CL; Bonastre J; Bachelot F; Davesne C; Gentile A; Hirlimann E; Sabourin JC; Berlie J; Rouëssé J
Bull Cancer; 2002 Jun; 89(6):635-42. PubMed ID: 12135864
[TBL] [Abstract][Full Text] [Related]
17. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of concurrent chemoradiation in comparison with radiation alone in locally advanced cervical cancer.
Manusirivithaya S; Sripramote M; Tangjitgamol S; Sanjareonsuttikul N; Pisarnturakit P
J Med Assoc Thai; 2005 Aug; 88(8):1035-44. PubMed ID: 16404829
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
20. [Macro-economic calculation of spending versus micro-economic follow-up of costs of breast cancer].
Borella L; Paraponaris A
Rev Epidemiol Sante Publique; 2002 Dec; 50(6):581-92. PubMed ID: 12515928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
